COBRE Center for Cancer Research Development

这一修订后的竞争性更新建立在科布雷癌症研究发展中心(CCRD)在指导有前途的初级研究人员走向独立方面的成功基础上。外部咨询和高级教员指导和咨询委员会(东非委员会和SFMAC)将在指导初级调查人员方面发挥重要作用。蛋白质组学和分子病理学核心将继续提供先进技术和专家指导，这是提高外部资金竞争力的资产。认识到罗德岛州的高癌症死亡率，CCRD将继续支持GI癌症领域的假设驱动研究。针对肝/胃肠道癌症干细胞的新合作努力的发展将由一个研究发展委员会监督。这一主题将充分利用罗德岛医院已经在进行的强大的肝脏和干细胞研究计划。五名具有重叠研究兴趣的有才华的研究人员将创造分享想法和富有成效的互动的机会。Chin博士将研究乙酰化依赖的STATS信号通路在人和大鼠肝细胞癌中癌症干细胞自我更新和转移中的作用。Chatterjee博士是一名研究员，于第5年加入CCRD，他将专注于RAF激酶抑制蛋白(RKIP)，这是一种潜在的化疗敏感性生物标记物，也是STAT3介导的人类结肠癌转移的抑制因子。桑德斯博士是一名新的研究人员，他将研究从胎儿和成人肝脏分离的双能肝脏前体细胞的有丝分裂信号表型，以及这些途径如何受到成人肝脏微环境的影响。阿尔图拉博士是另一位新的研究人员，他将研究乙酰化在Survivin的定位、二聚化和活性中所起的作用，Survivin是细胞分裂的调节因子和凋亡的抑制因子。莫斯博士是CCRD支持的研究人员，他的第一个RO1是他的第一个RO1，他将继续进行一项以胃动素-1/2为中心的新系列研究，这是在他的第一个科布雷资助周期中发现的两个新的肿瘤抑制基因。虽然扩大基础癌症研究将继续是CCRD的首要任务，但我们将通过CCRD之友加强筹款工作和扩大外展活动，旨在提高公众对癌症研究价值的认识。通过临床观察驱动的创新项目促进基础科学家和临床肿瘤学家之间的互动也将是一个高度优先的任务。在接下来的5年里，CCRD将扩大其在维持与州和联邦立法者和政策制定者对话方面的领导作用。CCRD将提供过渡到NCI指定的临床癌症中心所需的基础研究框架。

This revised competing renewal builds on the success of the COBRE Center for Cancer Research Development (CCRD) in guiding promising junior investigators towards independence. The External Advisory and Senior Faculty Mentoring and Advisory Committees (EAC and SFMAC) will play essential roles in mentoring of junior investigators. The Proteomics and Molecular Pathology Cores will continue to provide advanced technologies and expert guidance, assets that enhance competitiveness for extramural funds. Recognizing the high cancer mortality in Rhode Island, CCRD will continue to support hypothesis driven research in the area of GI Cancer. Development of new collaborative endeavors focused on stem cells in liver/GI cancer will be overseen by a Research Development Committee. This theme will take full advantage of the strong liver and stem cell research programs already ongoing at Rhode Island Hospital. Five talented investigators with overlapping research interests will generate opportunities for sharing of ideas and productive interaction. Dr. Chin will examine the role of acetylation dependent STATS signaling pathways in self-renewal and metastasis of cancer stem cells in human and rat hepatocellular carcinomas. Dr. Chatterjee, an investigator who joined CCRD in year 5, will focus on raf kinase inhibitory protein (RKIP), a potential biomarker for susceptibility to chemotherapy and an inhibitor of STAT3 mediated metastasis of human colon cancer. Dr. Sanders, a new investigator, will examine the mitogenic signaling phenotype of bipotent hepatic progenitors isolated from fetal and adult liver and how these pathways are influenced by the adult liver microenvironment. Dr. Altura, another new investigator will examine the role that acetylation plays in the localization, dimerization and activity of survivin as a regulator of cell division and an inhibitor of apoptosis. Dr. Moss, a CCRD supported investigator with his first RO1, will pursue a new line of research centered on gastrokine-1/2, two novel tumor suppressor genes identified during his first cycle of COBRE funding. Although expanding basic cancer research will continue to be the primary mission of CCRD, we will work through the Friends of CCRD to increase fundraising efforts and augment outreach activities aimed at increasing public awareness of the value of cancer research. Fostering interactions between basic scientists and clinical oncologists through innovative programs driven by clinical observation will also be a high priority. During the next 5 years, CCRD will expand its leadership role in sustaining a dialogue with State and Federal legislators and policy makers. CCRD will provide the basic research framework needed for transitioning into an NCI designated clinical cancer center.